Patents Assigned to Caelus Pharmaceuticals B.V.
  • Patent number: 10857189
    Abstract: A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a composition comprising pseudovitamin B12-producing bacteria, optionally in conjunction with mucin-degrading and/or propionate-producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vitamin B12 deficiency due to metformin treatment for type-2 diabetes, and to subjects having undergone bariatric surgery.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: December 8, 2020
    Assignee: Caelus Pharmaceuticals B.V.
    Inventor: Willem Meindert De Vos
  • Patent number: 10806758
    Abstract: A method for culturing and preserving the probiotic gut microorganism Eubacterium hallii is disclosed. The method provides an E. hallii preparation that is suitable for administration or ingestion to humans and that provides high E. hallii biomass yields. Preferably, the medium used for culturing E. hallii to high biomass yields comprises food grade components only, is free of any animal sources, and/or is kosher. Further, including a method of treating disease using the E. hallii preparation.
    Type: Grant
    Filed: January 2, 2017
    Date of Patent: October 20, 2020
    Assignee: Caelus Pharmaceuticals B.V.
    Inventors: Willem Meindert De Vos, Jozef Franciscus Maria Louis Seegers
  • Patent number: 9623055
    Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: April 18, 2017
    Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.
    Inventors: Max Nieuwdorp, Willem Meindert De Vos
  • Publication number: 20160317589
    Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 3, 2016
    Applicants: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.
    Inventors: Max Nieuwdorp, Willem Meindert De Vos
  • Patent number: 9433650
    Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: September 6, 2016
    Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.
    Inventors: Max Nieuwdorp, Willem Meindert De Vos